Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson Gets Punitive Damages in Risperdal Case Reduced to $6.8 Million

By David Jagielski - Jan 17, 2020 at 2:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The fine was initially set to $8 billion and was on top of a compensatory award totaling $680,000.

Healthcare giant Johnson & Johnson (JNJ 0.91%) got good news on Friday when a Philadelphia judge drastically reduced the $8 billion punitive damage verdict the company was initially ordered to pay in October down to just $6.8 million.

The original fine was awarded by a jury to a plaintiff who experienced unwanted side effects from the company's Risperdal medication, which is used to treat people with schizophrenia, bipolar disorder, and it also helps people with autism. The plaintiff in the case, Nicholas Murray, began taking the medication as a child to treat behaviors related to autism, but the drug caused the young man to grow breasts -- a condition called gynecomastia.

The punitive damages were in addition to a $680,000 compensatory award the plaintiff would receive. Johnson & Johnson challenged the ruling, and today it learned of the reduction to the punitive fees.

Prescription medication.

Image source: Getty Images.

Just one of many problems for J&J

Friday's ruling offers some much-needed positivity for Johnson & Johnson, as it has been under pressure for the past few years from product liability litigation. 

Some consumers alleged the company's baby powder products led them to develop ovarian cancer. There have also been problems relating to vaginal mesh products in Australia, where the company lost a case last year. Oklahoma came after J&J for its role in the opioid crisis and a judge ruled the company would be fined $572 million, which was reduced to $465 million in November.

Amid all these controversies, Johnson & Johnson's stock rose a modest 13% in 2019, well below what was a fantastic year for the markets that saw the S&P 500 climb 30%. Despite Friday's positive result, the healthcare stock was up less than 1%.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$181.09 (0.91%) $1.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.